Chimeric NKG2D-modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways

Cancer Research

Volumn 67, Issue 22, 2007, Pages 11029-11036

  Zhang, Tong ^a   Barber, Amorette ^a   Sentman, Charles L ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; CYTOKINE; FAS LIGAND; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; NATURAL KILLER CELL RECEPTOR NKG2D; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG INHIBITION; IN VITRO STUDY; LYMPH NODE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; SPLEEN; T CELL LYMPHOMA; T LYMPHOCYTE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERFERON TYPE II; LYMPH NODES; LYMPHOMA, T-CELL; MICE; MICE, INBRED C57BL; RECEPTORS, IMMUNOLOGIC; SPLEEN; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TREATMENT OUTCOME;

EID: 36348955143     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-2251     Document Type: Article

References (52)

1. Rossig C, Brenner MK. Genetic modification of T lymphocytes for adoptive immunotherapy. Mol Ther 2004;10:5-18.
2. Ho WY, Blattman JN, Dossett ML, Yee C, Greenberg PD. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 2003;3:431-7.
3. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001;411:380-4.
4. Ribas A, Butterfield LH, Glaspy JA, Economou JS. Cancer immunotherapy using gene-modified dendritic cells. Curr Gene Ther 2002;2:57-78.
5. Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003;3:35-45.
6. Kessels HW, Wolkers MC, van den Boom MD, van der Valk MA, Schumacher TN. Immunotherapy through TCR gene transfer. Nat Immunol 2001;2:957-61.
7. Zhang T, He X, Tsang TC, Harris DT. Transgenic TCR expression: comparison of single chain with full-length receptor constructs for T-cell function. Cancer Gene Ther 2004;11:487-96.
8. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126-9.
9. Zhang T, Lemoi BA, Sentman CL. Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy. Blood 2005;106:1544-51.
10. Zhang T, Barber A, Sentman CL. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor. Cancer Research 2006;66:5927-33.
11. Smyth MJ, Swann J, Cretney E, Zerafa N, Yokoyama M, Hayakawa Y. NKG2D function protects the host from tumor initiation. J Exp Med 2005;202:583-8.
12. Trapani JA, Smyth MJ. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol 2002;2:735-47.
13. Davidson WF, Giese T, Fredrickson TN. Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions. J Exp Med 1998;187:1825-38.
14. Schroder K, Hertzog PJ, Ravasi T, Hume, DA. Interferon-γ: an overview of signals, mechanisms and functions. J Leukoc Biol 2004;75:163-89.
15. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006;6:836-48.
16. Schmaltz C, Alpdogan O, Muriglan SJ, et al. Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation. Blood 2003;101:2440-5.
17. Nagoshi M, Goedegebuure PS, Burger UL, Sadanaga N, Chang MP, Eberlein TJ. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-γ and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes. J Immunol 1998;160:334-44.
18. Helmich BK, Dutton, RW. The role of adoptively transferred CD8 T cells and host cells in the control of the growth of the EG7 thymoma: factors that determine the relative effectiveness and homing properties of Tc1 and Tc2 effectors. J Immunol 2001;166:6500-8.
19. Hollenbaugh JA, Dutton RW. IFN-γ regulates donor CD8 T cell expansion, migration, and leads to apoptosis of cells of a solid tumor. J Immunol 2006;177:3004-11.
20. Sentman CL, Barber MA, Barber A, Zhang T. NK cell receptors as tools for cancer immunotherapy. Adv Cancer Res 2006;95:249-92.
21. Eriksson M, Meadows SK, Basu S, Mselle TF, Wira CR, Sentman CL. TLRs mediate IFN-γ production by human uterine NK cells in endometrium. J Immunol 2006;176:6219-24.
22. Roby KF, Taylor CC, Sweetwood JP, et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 2000;21:585-91.
23. Chakraborty M, Abrams SI, Camphausen K, et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 2003;170:6338-47.
24. Kataoka T, Shinohara N, Takayama H, et al. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. J Immunol 1996;156:3678-86.
25. Gilboa E. The makings of a tumor rejection antigen. Immunity 1999;11:263-70.
26. Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003;3:781-90.
27. Salih HR, Antropius H, Gieseke F, et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003;102:1389-96.
28. Sconocchia G, Lau M, Provenzano M, et al. The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions. Blood 2005;106:3666-72.
29. Koh CY, Blazar BR, George T, et al. Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood 2001;97:3132-7.
30. Mehrotra PT, Donnelly RP, Wong S, et al. Production of IL-10 by human natural killer cells stimulated with IL-2 and/or IL-12. J Immunol 1998;160:2637-44.
31. Gray JD, Hirokawa M, Ohtsuka K, Horwitz DA. Generation of an inhibitory circuit involving CD8+ T cells, IL-2, and NK cell-derived TGF-β: contrasting effects of anti-CD2and anti-CD3. J Immunol 1998;160:2248-54.
32. Winter H, Hu HM, Urba WJ, Fox BA. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L). J Immunol 1999;163:4462-72.
33. Blankenstein T, Qin Z. The role of IFN-β in tumor transplantation immunity and inhibition of chemical carcinogenesis. Curr Opin Immunol 2003;15:148-54.
34. Wigginton JM, Gruys E, Geiselhart L, et al. IFN-γ and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J Clin Invest 2001;108:51-62.
35. Beatty G, Paterson Y. IFN-γ-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-γ. J Immunol 2001;166:2276-82.
36. Corthay A, Skovseth DK, Lundin KU, et al. Primary antitumor immune response mediated by CD4+ T cells. Immunity 2005;22:371-83.
37. Fan Z, Yu P, Wang Y, et al. NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumors. Blood 2006;107:1342-51.
38. Oshikawa K, Shi F, Rakhmilevich AL, Sondel PM, Mahvi DM, Yang NS. Synergistic inhibition of tumor growth in a murine mammary adenocarcinoma model by combinational gene therapy using IL-12, pro-IL-18, and IL-1β converting enzyme cDNA. Proc Natl Acad Sci U S A 1999;96:13351-6.
39. Di Carlo E, Comes A, Orengo AM, et al. IL-21 induces tumor rejection by specific CTL and IFN-γ-dependent CXC chemokines in syngeneic mice. J Immunol 2004;172:1540-7.
40. Eager R, Nemunaitis J. GM-CSF gene-transduced tumor vaccines. Mol Ther 2005;12:18-27.
41. Sprent J, Surh CD. T cell memory. Annu Rev Immunol 2002;20:551-79.
42. Wang LX, Kjaergaard J, Cohen PA, Shu S, Plautz GE. Memory T cells originate from adoptively transferred effectors and reconstituting host cells after sequential lymphodepletion and adoptive immunotherapy. J Immunol 2004;172:3462-8.
43. Kursar M, Bonhagen K, Fensterle J, et al. Regulatory CD4+CD25+ T cells restrict memory CD8+ T cell responses. J Exp Med 2002;196:1585-92.
44. Ahmadzadeh M, Rosenberg SA. TGF-β1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells. J Immunol 2005;174:5215-23.
45. Wang RF. Immune suppression by tumor-specific CD4+ regulatory T-cells in cancer. Semin Cancer Biol 2006;16:73-9.
46. Kilinc MO, Aulakh KS, Nair RE, et al. Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors. J Immunol 2006;177:6962-73.
47. Leen AM, Rooney CM, Foster AE. Improving T cell therapy for cancer. Annu Rev Immunol 2007;25:243-65.
48. Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 2002;99:16168-73.
49. Melchionda F, Fry TJ, Milliron MJ, McKirdy MA, Tagaya Y, Mackall CL. Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool. J Clin Invest 2005;115:1177-87.
50. Teague RM, Sather BD, Sacks JA, et al. Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors. Nat Med 2006;12:335-41.
51. Lanzavecchia A, Sallusto F. Progressive differentiation and selection of the fittest in the immune response. Nat Rev Immunol 2002;2:982-7.
52. Gattinoni L, Klebanoff CA, Palmer DC, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 2005;115:1616-26.